$NUVB News

Cantor Fitzgerald Initiates Coverage of Nuvation Bio (NUVB) with Overweight Recommendation

Cantor Fitzgerald Initiates Coverage On Nuvation Bio with Overweight Rating

Nuvation Bio Says FDA Grants Fast Track Designation For Safusidenib, Investigational, Oral, Brain-Penetrant Selective Inhibitor Of Mutant IDH1

JP Morgan Initiates Coverage of Nuvation Bio (NUVB) with Overweight Recommendation

JP Morgan Initiates Coverage On Nuvation Bio with Overweight Rating, Announces Price Target of $13

Nuvation Bio Q2 Earnings Call Highlights

RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $20

Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates

Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcript

Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Nuvation Bio Q2 EPS $(0.18) Beats $(0.19) Estimate, Sales $31.687M Beat $27.505M Estimate

Do IBTROZI’s TRUST Data Shape Nuvation Bio’s (NUVB) Edge in Targeted Lung Cancer Therapy?

Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Nuvation Bio Announces New Subgroup Analyses Of Phase 2 TRUST-I And TRUST-II Data For IBTROZI In ROS1+ NSCLC Will Be Presented At WCLC And ESMO

Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?

Wall Street Analysts See a 94.32% Upside in Nuvation Bio (NUVB): Can the Stock Really Move This High?

HC Wainwright & Co. Maintains Buy on Nuvation Bio, Raises Price Target to $21

Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target

Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Nuvation Bio's Safusidenib Clinical Program, Ibtrozi Opportunity Create Favorable Setup, RBC Says